ArticleJournal of medicinal chemistry2024

Advancing Cancer Immunotherapy through Engineering New PD-L1 Degraders: A Comprehensive Study from Small Molecules to PD-L1-Specific Peptide-Drug Conjugates.

Zekun Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.